Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Aldeyra Therapeutics, Inc. (ALDX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 11/05/2020 |
8-K
| Quarterly results |
| 08/06/2020 |
8-K
| Quarterly results |
| 05/07/2020 |
8-K
| Quarterly results |
| 08/08/2019 |
8-K
| Quarterly results |
| 05/09/2019 |
8-K
| Quarterly results |
| 11/14/2018 |
8-K
| Quarterly results |
| 08/09/2018 |
8-K
| Quarterly results |
| 03/29/2018 |
8-K
| Quarterly results|
Docs:
|
"Aldeyra Therapeutics Announces Year End 2017 Financial Results LEXINGTON, Mass., Mar. 29, 2018 /PRNewswire/ — Aldeyra Therapeutics, Inc. , a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with inflammatory diseases, today announced financial results for the year ended December 31, 2017. “2017 was a productive year for Aldeyra, highlighted by favorable clinical results in dry eye disease and allergic conjunctivitis, initiation of a Phase 3 clinical trial in noninfectious anterior uveitis, and receipt of orphan drug designation for reproxalap in Sjögren-Larsson Syndrome,” commented Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra. “Our progress has continued in 2018, having recently enrolled the first patient into our P..." |
|
| 11/09/2017 |
8-K
| Quarterly results|
Docs:
|
"Aldeyra Therapeutics Announces Third Quarter 2017 Financial Results LEXINGTON, Mass., November 9, 2017 /PRNewswire/ — Aldeyra Therapeutics, Inc. , a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced financial results for the quarter ended September 30, 2017. “The announcement of clinical results in dry eye disease in the third quarter marks the fifth positive Phase 2 clinical trial of our lead aldehyde trap, reproxalap, formerly known as ADX-102,” commented Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra. “Given the consistent clinical activity of reproxalap across large-market and orphan diseases, we now look to expand our pipeline with new molecules in ne..." |
|
| 08/08/2017 |
8-K
| Quarterly results|
Docs:
|
"Aldeyra Therapeutics Announces Second Quarter 2017 Financial Results Lexington, MA, August 8, 2017 - Aldeyra Therapeutics, Inc. , a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to aldehydes, today announced its financial results for the quarter ended June 30, 2017. “With the release of allergic conjunctivitis Phase 2b clinical trial results in the second quarter, we were pleased to announce our third Phase 3 clinical program,” commented Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra. “We are determined to continue to advance our novel aldehyde trap platform toward commercialization, with the goal of providing a novel pharmacologic approach to patients with limited safe and effective therapeutic opti..." |
|
| 05/15/2017 |
8-K
| Form 8-K - Current report |
| 03/30/2017 |
8-K
| Form 8-K - Current report |
| 11/14/2016 |
8-K
| Form 8-K - Current report |
| 08/10/2016 |
8-K
| Form 8-K - Current report |
| 03/30/2016 |
8-K
| Form 8-K - Current report |
| 08/11/2015 |
8-K
| Quarterly results|
Docs:
|
"Aldeyra Therapeutics Reports Second Quarter and Year to Date 2015 Financial Results and Provides Development Updates LEXINGTON, Mass., August 11, 2015 — Aldeyra Therapeutics, Inc. , a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced its financial results for the second quarter and six months ended June 30, 2015. Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, commented, “During the recent quarter and entering the second half of the year, we have continued to focus on the development of our lead product candidate, NS2, a novel aldehyde trap. Importantly, we are excited to announce the addition of a new clinical program, allergic conjunctivitis, a common inflammatory ocular disease that is not adequately treat..." |
|
| 05/13/2015 |
8-K
| Quarterly results |
| 11/12/2014 |
8-K
| Quarterly results|
Docs:
|
"Second Amendment to Loan and Security Agreement",
"Aldeyra Therapeutics Reports Third Quarter and Year to Date 2014 Financial Results Lexington, MA, November 10, 2014 - Aldeyra Therapeutics, Inc. , a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced its financial results for the third quarter and nine months ended September 30, 2014. Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, commented, “We continued to execute our business strategy during the third quarter, and, by year end, we expect to file Investigational Drug Applications for clinical testing of our lead product candidate, NS2, for the treatment of Sjögren-Larsson Syndrome and acute anterior uveitis. Accordingly, we remain on track with the initiation of our clinical trials in the near term, wi..." |
|
| 08/04/2014 |
8-K
| Quarterly results|
Docs:
|
"Aldeyra Therapeutics Reports Second Quarter 2014 Financial Results Burlington, MA, August 4, 2014 - Aldeyra Therapeutics, Inc. , a biotechnology company focused on the development of products to treat diseases thought to be related to free aldehydes, today announced its financial results for the second quarter ended June 30, 2014. Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, commented, “We continue to prepare for upcoming clinical trials and are on schedule to file Investigational Drug Applications for two rare diseases, Sjögren-Larsson Syndrome and acute anterior uveitis, by the end of the year, and we continue to expect data from these trials next year. For Sjögren-Larsson Syndrome, there are no FDA-approved therapies, and acute anterior uveitis is typically treate..." |
|
| 06/11/2014 |
8-K
| Quarterly results|
Docs:
|
"Aldeyra Therapeutics Reports First Quarter 2014 Financial Results Burlington, MA, June 11, 2014 - Aldeyra Therapeutics, Inc. , a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced its financial results for the first quarter ended March 31, 2014. “The past few months have been important for Aldeyra Therapeutics,” said Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra. “Most notably, we completed our initial public offering, which provided us with net proceeds of approximately $11 million to support our planned clinical trials for our lead product candidate, NS2, in Sjögren-Larsson Syndrome and acute anterior uveitis. We remain on track to report data from these two clinical trials in 2015. We believe that the..." |
|
|
|